COLO 699 N

Source biologique

human lymph

Niveau de qualité


Mode de croissance



Not specified




Not specified


Not specified


cell culture | mammalian: suitable

Maladie(s) pertinente(s)


Expédié(e)(s) dans

dry ice

Temp. de stockage


Catégories apparentées

Description générale

COLO 699 N cells, a non-small cell lung cancer cell line is useful in subcutaneous xenografts studies to mimic in vivo model of human lung cancer. It finds applications in stable isotope-based proteome analysis.

Origine de la lignée cellulaire

Human lung cancer

Description de la lignée cellulaire

Derived from the pleural fluid of a 57 year old female with lung cancer. Please note: This cell line was found to be indistinguishable from cell lines RPMI 7932 & COLO 738 by STR PCR DNA profiling. At ECACC the STR PCR profile of all stocks of this cell line match the profile of the original source material received at ECACC. However, it is not clear if the cell lines COLO 699N, RPMI 7932 & COLO 738 were originally derived from the same individual as the profiles suggest. The cell lines COLO 699N, RPMI 7932 & COLO 738 were received from the same depositor. If we are able to obtain clarification of the relationship between these cell lines this information will be updated.


COLO 699 N has been used in cytotoxicity studies with Tegaran and 13-methyltetradecanoic acid (13-MTD).
Tumourigenicity studies

Profil d'ADN

STR-PCR Data: Amelogenin: X
CSF1PO: 10
D13S317: 11
D16S539: 12
D5S818: 11,12
D7S820: 11,13
THO1: 9,9.3
vWA: 17

Milieu de culture

RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).

Procédure de repiquage

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm2using 0.25% trypsin/EDTA; 5% CO2; 37°C.

Autres remarques

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.


NONH for all modes of transport

WGK Allemagne


Flash Point(F)

Not applicable

Point d'éclair C

Not applicable

Certificat d'analyse
Certificat d'origine
A S Boehle et al.
The Annals of thoracic surgery, 69(4), 1010-1015 (2000-05-09)
Overall prognosis in human lung cancer is still poor. A highly reproducible, easy to perform in vivo model, which closely resembles the clinical features of advanced human lung cancer, is required for the evaluation of novel therapies. Tumor cells, originated...
Kathrin Grundner-Culemann et al.
Journal of proteomics, 130, 1-10 (2015-09-13)
Non-small cell lung cancer (NSCLC) cell lines are widely used model systems to study molecular aspects of lung cancer. Comparative and in-depth proteome expression data across many NSCLC cell lines has not been generated yet, but would be of utility...
H G Morse et al.
Cancer genetics and cytogenetics, 69(2), 108-112 (1993-09-01)
Melanoma cell lines initiated from metastases excised at the same time from multiple sites in a patient reflect a single clone origin. The similarities of the karyotypes of these lines depend upon the site of excision, the selective survival in...
Panagiotis Parsonidis et al.
PloS one, 15(10), e0240969-e0240969 (2020-10-22)
The aim of this study is to evaluate the potential health effects of Tegaran Formula ZhenHua, a nutritional supplement used mainly by cancer patients. Its active ingredients and cytotoxicity was assessed with analytical methods and viability assays, respectively. The analytical...

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique

Réseaux sociaux

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Recherche. Développement. Production

Nous sommes un des tout premiers fournisseurs du secteur mondial des Sciences de la vie proposant des solutions et des services pour la recherche, le développement et la production en biotechnologies, et le développement et la production de produits thérapeutiques pharmaceutiques.

© 2021 Merck KGaA, Darmstadt, Allemagne et/ou ses sociétés affiliées. Tous droits réservés.

La reproduction d'une quelconque partie du contenu de ce site est strictement interdite sans autorisation.